News Agency
The Times

Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors

  • Written by PR Newswire
Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule ERK1/2 Inhibitor ATG-017 in Patients with Advanced Solid Tumors
  • ATG-017 is a small molecule ERK1/2 inhibitor and Antengene has obtained exclusive global rights to develop, commercialize and manufacture ATG-017.
  • IND clearance enables Antengene to initiate the combination portion of the Phase I "ERASER" clinical trial in the United States (U.S.) to evaluate the safety, pharmacokinetics, and preliminary efficacy...

Read more: Antengene Receives U.S. FDA Clearance of IND Application for Phase I Trial of Small Molecule...

Executive Recruitment And The Value Of Executive Recruitment Agencies In Modern Hiring

Finding the right leadership talent is one of the most important decisions an organisation can make. Strong leaders influence company culture, business performance, strategic direction, and long-term growth. As competition for experienced executives continues to increase, executive recruitment has become a... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion